Skip to main content
The Progressive Supranuclear Palsy Clinical Deficits Scale
- Piot, Ines;
- Schweyer, Kerstin;
- Respondek, Gesine;
- Stamelou, Maria;
- Sckopke, Philipp;
- Schenk, Thomas;
- Goetz, Christopher G;
- Stebbins, Glenn T;
- Höglinger, Günter U;
- Gasser, Thomas;
- Hermann, Andreas;
- Höglinger, Günter;
- Höllerhage, Matthias;
- Kimmich, Okka;
- Klockgether, Thomas;
- Levin, Johannes;
- Machetanz, Gerrit;
- Osterrath, Antje;
- Palleis, Carla;
- Prudlo, Johannes;
- Spottke, Annika;
- Berg, Daniela;
- Bürk, Katrin;
- Claßen, Joseph;
- Eggers, Carsten;
- Greuel, Andrea;
- Grimm, Max‐Joseph;
- Hermann, Lennard;
- Iankova, Vassilena;
- Jahn, Klaus;
- Jost, Wolfgang;
- Klietz, Martin;
- Kühn, Andrea;
- Marxreiter, Franz;
- Paschen, Steffen;
- Poetter‐Nerger, Monika;
- Preisl, Marie‐Therese;
- Prilop, Lisa;
- Tönges, Lars;
- Trenkwalder, Claudia;
- Warnecke, Tobias;
- Wegner, Florian;
- Winkler, Jürgen;
- Antonini, Angelo;
- P, Kailash P;
- L, Adam L;
- Colosimo, Carlo;
- Compta, Yaroslau;
- Corvol, Jean‐Christophe;
- I, Lawrence I;
- Höglinger, Günter U;
- E, Anthony E;
- Litvan, Irene;
- R, Huw R;
- Nilsson, Christer;
- Pantelyat, Alexander;
- Respondek, Gesine;
- Stamelou, Maria
- et al.
Published Web Location
https://pubmed.ncbi.nlm.nih.gov/31951049-the-progressive-supranuclear-palsy-clinical-deficits-scale/?from_term=The+Progressive+Supranuclear+Palsy+Clinical+Deficits+Scale.&from_pos=1No data is associated with this publication.
Abstract
Background
There is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes.Objective
To develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes.Methods
The Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts).Results
Cognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62% males, 35% variant phenotypes). Mean Progressive Supranuclear Palsy Clinical Deficits Scale completion time was 4 minutes. The Progressive Supranuclear Palsy Clinical Deficits Scale total score correlated with existing scales (e.g., Progressive Supranuclear Palsy Rating Scale: R = 0.88; P < 0.001). Individual Progressive Supranuclear Palsy Clinical Deficits Scale items correlated well with similar constructs in existing scales. Internal consistency (Cronbach's alpha: 0.75), inter-rater reliability (0.96), and test-retest stability (0.99) were acceptable. The PSP-CDS showed significant 12-month change (baseline, 8.6 ± 3.6; follow-up: 10.8 ± 3.6; annualized difference: 3.4 ± 3.4; n = 49; P < 0.0001). Sample sizes required per arm for a two-arm, 1-year follow-up therapeutic trial to detect 50% change in Progressive Supranuclear Palsy Clinical Deficits Scale progression was estimated to be 65 (two-sided, two-sample t test).Conclusion
The Progressive Supranuclear Palsy Clinical Deficits Scale is a rapidly completed, clinimetrically sound scale for clinical care and research involving PSP. © 2020 International Parkinson and Movement Disorder Society.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.